Drugs / CNTX-6970
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03787004 | Aug 2017 → Aug 2018 | chronic pain syndrome | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05025787 | Oct 2021 → Jun 2024 | osteoarthritis, knee | Maurizio Fava, MD | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTX-6970 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05025787 ↗ |
| Action | Inhibit | “pharmacologic blockade of specific chemokine receptors with this compound” PMID 41468282 ↗ Jan 2026 |
| Modality | Small molecule | “a small molecule” PMID 41468282 ↗ Jan 2026 |
| Route | Oral | “Oral dose CNTX-6970” NCT03787004 ↗ |
| Target | CCR2 | “cytokine chemokine receptor type 2 (CCR2)” PMID 41468282 ↗ Jan 2026 |
| Target | CCR5 | “CCR5 antagonist” PMID 41468282 ↗ Jan 2026 |